Secaucus, New Jersey-based Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the United States and internationally. Valued at a market capitalization of $23 billion, the company develops and delivers diagnostic information services, including routine, non-routine, and advanced clinical testing, anatomic pathology testing, and other diagnostic services. The company's shares have outperformed the broader market over the past year and in 2026. DGX stock has surged 21.8% over t ...

Core Insights - Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and services, valued at $20.6 billion, with a national network of laboratories and patient service centers [1] Performance Overview - DGX shares have outperformed the broader market, gaining 15.4% over the past year compared to the S&P 500 Index's 12.3% increase [2] - Year-to-date, DGX stock is up 23.3%, surpassing the S&P 500's 12.9% rise [2] Comparison with Industry Peers - DGX's performance is also superior to the SPDR S&P Health Care Services ETF (XHS), which has gained about 9.8% over the past year [3] - On a year-to-date basis, DGX's returns outshine the ETF's 12.8% gains [3] Financial Results - In Q3, DGX reported an adjusted EPS of $2.60, exceeding Wall Street's expectation of $2.51, with revenue of $2.8 billion, beating the forecast of $2.7 billion [4] - For the full year, DGX expects adjusted EPS in the range of $9.76 to $9.84 and revenue between $10.96 billion and $11 billion [4] Analyst Expectations - Analysts project DGX's EPS to grow 9.6% to $9.79 for the current fiscal year [5] - DGX has consistently beaten consensus estimates in the last four quarters, with a current consensus rating of "Moderate Buy" from 18 analysts [5] Analyst Ratings and Price Targets - The current analyst configuration is less bullish than three months ago, with nine analysts suggesting a "Strong Buy" [6] - Piper Sandler Companies maintained a "Neutral" rating on DGX, raising the price target to $200, indicating a potential upside of 7.6% [6] - The mean price target of $198.71 suggests a 6.9% premium, while the highest price target of $215 indicates a potential upside of 15.6% [6]